Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Seasonal Affective Disorder

Seasonal Affective Disorder (SAD) · Circadian Mood Disruption

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

20 human trials, about 200 studies, >30,000 participants across prevalence and treatment studies. The written rationale for this grade is still being prepared.

FDA
No drug approved specifically for SAD; light boxes are unregulated wellness devices, not FDA-cleared for SAD. Bupropion XL is FDA-approved for SAD prevention.
WADA
Not applicable (clinical condition)

Reference only. Not medical advice.

What can go wrong

SAD is a clinical depressive disorder, not a lifestyle complaint. Depression carries suicide risk, and SAD can heighten suicidality during peak episodes. This entry is educational and is not self-diagnosis or self-treatment guidance, and it does not provide dosing, timing, or device protocols. Anyone with persistent low mood, hopelessness, or thoughts of self-harm should consult a qualified mental-health provider (psychiatrist, psychologist, or physician); in a crisis, contact local emergency services or a suicide prevention line such as 988 in the US. Light therapy is not risk-free: it can trigger hypomania or mania in people with bipolar disorder and should be supervised in that group, and headache, eye strain, agitation, nausea, and sleep disruption occur in a minority of users. People with eye disease, retinal conditions, or on photosensitizing medication should be assessed by a clinician before any use. Light boxes sold for SAD are unregulated wellness products with no standardized output; device choice, intensity, and timing are clinical decisions that should be made with a qualified provider rather than self-directed.

Seasonal affective disorder is a pattern of recurrent major depressive episodes that begin in autumn or winter and remit in spring. DSM-5-TR does not list it as a separate disorder; it is the 'with seasonal pattern' specifier applied to major depressive disorder or bipolar disorder. Rosenthal and colleagues at the US National Institute of Mental Health first described the syndrome in 1984, after Rosenthal, who grew up in the milder light of Johannesburg, noticed his own mood drop in the darker winters of the northeastern United States. Winter-pattern SAD typically brings low mood with atypical features: hypersomnia, increased appetite, carbohydrate craving, and weight gain. The leading mechanistic account is Alfred Lewy's phase-shift hypothesis. Shorter winter days delay the internal clock relative to the sleep schedule in most patients, measured as a later dim-light melatonin onset, and morning bright light advances the clock back toward alignment. The evidence is best read in three parts that the disorder's reality does not equalize. Acute treatment with bright light has the strongest support: the American Psychiatric Association's commissioned meta-analysis (Golden et al. 2005) reported an effect size of 0.84, and CANMAT lists light as first-line for seasonal depression. Prevention of episodes is far weaker: a 2019 Cochrane review found only one small randomized trial and rated the certainty very low. And the construct itself is contested, with a 2016 US survey finding no seasonal or latitude signal in depression scores. Light is also nearly impossible to blind, so the size of its true effect over placebo remains debated even where the direction favors it. SAD sits on a spectrum from subsyndromal winter blues to a clinical depressive disorder that can carry suicide risk and warrants professional assessment.

Recurrent winter-pattern depression tied to a delayed circadian clock, not the same thing as the winter blues.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Clinical framing of recurrent winter-pattern depression for evaluation by a qualified provider
  • Context for bright light therapy as a first-line clinician-guided option for acute seasonal depression, with the placebo-blinding caveat stated
  • Context for dawn simulation as a lower-intensity alternative studied in controlled trials
  • Understanding circadian phase (a delayed clock in most, but not all, patients) as a mechanism and a timing rationale for morning light
  • Distinguishing acute treatment evidence (stronger) from prevention evidence (very-low certainty) when weighing options with a provider

What people get wrong

  • Often saidA SAD light box is FDA-approved, so it is medically vetted for safety and dose.

    ActuallyNo light box is FDA-approved or FDA-cleared as a treatment for SAD. They are marketed as general wellness devices outside FDA premarket review, so output, spectrum, and dosing are not standardized across products. The only FDA-approved product for SAD is the drug bupropion XL, cleared in 2006 for prevention of seasonal depressive episodes, not a device.

  • Often saidThe winter blues and seasonal affective disorder are the same thing.

    ActuallyThey are not. The winter blues (subsyndromal SAD) is a milder seasonal mood dip that does not meet criteria for a major depressive episode; a 2025 meta-analysis pooled its prevalence near 9 percent versus about 5 percent for full SAD. Clinical SAD is a depressive disorder that can impair functioning and elevate suicide risk.

  • Often saidLight therapy clearly beats placebo and the evidence is settled.

    ActuallyThe direction favors light and the American Psychiatric Association meta-analysis (Golden et al. 2005) reported a strong effect size of 0.84, but light is nearly impossible to blind and advertising-recruited trials enroll believers. Trials with a credible placebo-light control show smaller effects than those without one, so the true size of the advantage over placebo is still debated even though multiple controlled trials favor light.

  • Often saidSeasonal depression rises predictably with latitude, so the darkest places are the most depressed.

    ActuallyLatitude is associated with prevalence but does not determine it. A 2025 meta-analysis found higher latitude significantly associated with more SAD, yet the Tromso Study in Arctic Norway (n=8,951) found no significant seasonal difference in self-reported mental distress, and a 2016 US survey found no latitude or sunlight signal at all. Culture, expectations, and a positive wintertime mindset appear to moderate the daylength effect.

Who profits, and who pushes back

  • Dr. Norman E. Rosenthal

    Promotes itPsychiatrist; coined 'seasonal affective disorder' (1984); author of Winter Blues

    Originated the SAD construct and light-therapy treatment at NIMH. Author of consumer books on SAD and a long-standing public advocate for light therapy; book royalties and speaking are a commercial interest, so treat his positive framing as the originator's own view.

  • Center for Environmental Therapeutics (CET)

    Promotes itNonprofit founded by light-therapy researchers including Michael Terman

    CET publishes SAD treatment guidance and self-assessment tools and has historically had ties to light-device commercialization and licensing. States that morning bright light is effective; treat efficacy framing as the organization's claim, not Enel-asserted.

  • Dr. Charmane Eastman

    Pushes backRush University Medical Center, circadian researcher; author of a landmark placebo-controlled SAD light trial

    We found that bright light had a specific antidepressant effect beyond placebo, but it took at least three weeks to appear and the placebo response in these trials is unusually large; because light cannot be blinded, controlling that placebo response is essential before claiming a big effect.

  • Steven G. LoBello (with Megan Traffanstedt and Sheila Mehta)

    Pushes backAuburn University at Montgomery; authors of the 2016 Clinical Psychological Science construct-validity study

    In a large US sample, depression scores were unrelated to season, latitude, or sunlight exposure; our results do not support the validity of a seasonally related subtype of major depression at the population level.

  • Dr. Kari Leibowitz

    Pushes backHealth psychologist, Stanford PhD; Fulbright researcher in Tromso, Norway

    Above the Arctic Circle, people did not show the wintertime depression you would predict from daylength; a positive wintertime mindset was associated with every measure of wellbeing we examined, so biology is not the whole story.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
Europe40%
North America38%
East Asia12%
Other10%

Research published from: Global, higher-latitude bias.

How we got here

Treating mood and illness with light is ancient. Heliotherapy, deliberate exposure to sunlight, is documented across Ancient Egypt, Greece, India, and China more than two thousand years ago; the Greek historian Herodotus wrote that sun exposure strengthened the body, and Roman law recognized a right to sunlight. Solar and light symbolism in healing recurs across non-Western traditions, including Ayurvedic and Chinese medical practice, though specific seasonal-depression frameworks are a modern construction and the older record is largely about sunlight for physical disease rather than mood. Northern peoples developed their own responses to the long dark: Scandinavian and other Nordic cultures built winter social and lighting customs, candlelight and communal gatherings, around the polar darkness, and modern research in Tromso, Norway describes a wintertime mindset that may buffer against winter low mood. Modern phototherapy began with the Danish physician Niels Ryberg Finsen, who won the 1903 Nobel Prize in Physiology or Medicine for treating lupus vulgaris with concentrated light; the Swiss physician Auguste Rollier opened heliotherapy clinics in the Alps in the early twentieth century. The circadian-mood link arrived in 1984, when Norman Rosenthal and colleagues at the US National Institute of Mental Health named seasonal affective disorder. Alfred Lewy's group established that light suppresses human melatonin and later advanced the phase-shift hypothesis, and Michael Terman, Charmane Eastman, and David Avery ran the controlled trials that defined morning timing and placebo design.

  1. 1903Niels Finsen awarded Nobel Prize for medical light therapy
  2. 1980Lewy and colleagues show bright light suppresses human melatonin (Science)
  3. 1984Rosenthal et al. name SAD and report preliminary light therapy in 29 patients (Archives of General Psychiatry)
  4. 1998Eastman et al. and parallel trials establish morning light as superior to evening, and as beating a credible placebo on strict remission criteria (Archives of General Psychiatry)
  5. 2005Golden et al. American Psychiatric Association meta-analysis reports a bright-light effect size of 0.84 for SAD (American Journal of Psychiatry)
  6. 2006Can-SAD RCT (Lam et al.): light therapy and fluoxetine show comparable efficacy, 67% response each (American Journal of Psychiatry); Lewy et al. formalize the phase-shift hypothesis (PNAS); FDA approves bupropion XL for SAD prevention
  7. 2016Traffanstedt, Mehta & LoBello report no seasonal, latitude, or sunlight association in a US depression survey, questioning the seasonal modifier (Clinical Psychological Science)
  8. 2019Cochrane review (Nussbaumer-Streit) finds only one eligible RCT, n=46, and very-low-certainty evidence for light therapy to prevent SAD
  9. 2025Global meta-analysis (Kim & Kim; 24 studies, 32,866 participants) links higher latitude to higher SAD and subsyndromal SAD prevalence; a separate network meta-analysis rates between-light-color comparisons low to very low certainty

At a glance

DSM-5-TR status
A 'with seasonal pattern' specifier of major depression or bipolar disorder, not a standalone diagnosis
Standard light protocol
10,000 lux, ~30 min, early morning
Sex ratio
Roughly 4:1 female to male
US prevalence range
~1% (Florida) to ~9% (Alaska)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Seasonal Affective Disorder. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources